Defying Multidrug Resistance! Modulation of Related Transporters by Flavonoids and Flavonolignans.
Christopher S ChambersJitka ViktorováKateřina ŘehořováDavid BiedermannLucie TurkováTomáš MacekVladimir KrenKateřina ValentováPublished in: Journal of agricultural and food chemistry (2019)
Multidrug resistance (MDR) is a major challenge for the 21th century in both cancer chemotherapy and antibiotic treatment of bacterial infections. Efflux pumps and transport proteins play an important role in MDR. Compounds displaying inhibitory activity toward these proteins are prospective for adjuvant treatment of such conditions. Natural low-cost and nontoxic flavonoids, thanks to their vast structural diversity, offer a great pool of lead structures with broad possibility of chemical derivatizations. Various flavonoids were found to reverse both antineoplastic and bacterial multidrug resistance by inhibiting Adenosine triphosphate Binding Cassette (ABC)-transporters (human P-glycoprotein, multidrug resistance-associated protein MRP-1, breast cancer resistance protein, and bacterial ABC transporters), as well as other bacterial drug efflux pumps: major facilitator superfamily (MFS), multidrug and toxic compound extrusion (MATE), small multidrug resistance (SMR) and resistance-nodulation-cell-division (RND) transporters, and glucose transporters. Flavonoids and particularly flavonolignans are therefore highly prospective compounds for defying multidrug resistance.
Keyphrases
- low cost
- multidrug resistant
- endothelial cells
- early stage
- metabolic syndrome
- drug resistant
- high resolution
- single cell
- signaling pathway
- emergency department
- squamous cell carcinoma
- radiation therapy
- bone marrow
- binding protein
- insulin resistance
- small molecule
- mesenchymal stem cells
- smoking cessation
- protein protein
- skeletal muscle
- pluripotent stem cells
- glycemic control
- genome wide identification